Kyverna Therapeutics (NASDAQ:KYTX) Trading Up 6.2% – Should You Buy?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX)’s share price was up 6.2% during mid-day trading on Monday . The stock traded as high as $10.54 and last traded at $10.5450. Approximately 459,658 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 736,538 shares. The stock had previously closed at $9.93.

Kyverna Therapeutics News Summary

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: Registrational KYSA-8 primary analysis: A single dose of miv-cel met the trial’s primary endpoint (T25FW) with a statistically significant, durable improvement in mobility (median 46% improvement) and 81% of patients achieving clinically meaningful gains; all 26 patients were off chronic immunotherapies through last follow-up. Kyverna says it is preparing a BLA submission. GlobeNewswire: KYSA-8 Primary Analysis
• Positive Sentiment: Strong myasthenia gravis (gMG) data: Longer-term Phase 2 results show deep, durable responses through 52 weeks and 100% response in the small cohort, boosting confidence in later‑stage development for a second indication. These data increase the number of near-term regulatory and commercial value drivers. GlobeNewswire: gMG Data
• Positive Sentiment: Institutional and analyst support: Recent large institutional buys and at least one Wall Street upgrade/strengthened “buy” have lifted sentiment and underline belief in KYTX’s upside if pivotal/regulatory execution succeeds. QuiverQuant Coverage
• Neutral Sentiment: Market reaction intraday vs after-hours: Coverage and headlines triggered an after-hours rally despite intraday weakness, reflecting volatile sentiment as investors parse the details and timing of regulatory filings and commercialization plans. MSN: After-Hours Move
• Negative Sentiment: Small, single-arm sample and execution risks: Analysts and commentators warn the KYSA‑8 cohort (n=26) is small and uncontrolled, raising questions about generalizability, potential FDA requirements for additional data, and dilution/execution risk despite promising signals. Seeking Alpha: Caution on Small Sample

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KYTX shares. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Kyverna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.67.

Kyverna Therapeutics Stock Performance

The stock has a market capitalization of $587.75 million, a P/E ratio of -2.66 and a beta of 2.62. The firm has a 50-day moving average of $8.53 and a 200 day moving average of $8.09. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kyverna Therapeutics by 16.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock valued at $16,569,000 after acquiring an additional 250,418 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $15,667,000. AIGH Capital Management LLC bought a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $14,100,000. Vanguard Group Inc. lifted its holdings in shares of Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock valued at $7,936,000 after acquiring an additional 9,858 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $9,220,000. 18.08% of the stock is owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.